Hypertension, systemic inflammation and body weight in relation to lung function impairmentan epidemiological study

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 6, Issue 4, 2009, Pages 250-255

  Margretardottir, Olof Birna ^a   Thorleifsson, Sigurdur James ^a   Gudmundsson, Gunnar ^a,b   Olafsson, Isleifur ^b   Benediktsdottir, Bryndis ^a   Janson, Christer ^c   Buist, A Sonia ^d   Gislason, Thorarinn ^a,b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c UPPSALA UNIVERSITY   (Sweden)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Airflow obstruction; Cytokines; Hypertension; Obesity; Systemic inflammation

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; THIAZIDE DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; ICELAND; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING;

ADULT; ANALYSIS OF VARIANCE; BODY WEIGHT; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; HYPERTENSION; ICELAND; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SMOKING;

EID: 70350433688     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550903049157     Document Type: Article

References (32)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD)Workshop summary. Am J Respir Crit Care Med 2001; 163(5):1256-1276.
2. Mannino DM, Buist AS. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet 2007 Sep 1; 370(9589):765-773. Review.
3. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail 2006 Nov; 8(7):706-711. Review.
4. Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE, Colditz GA, Speizer FE, Barr RG, Camargo CA Jr. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004 Oct; 27(10):2478-2484.
5. Jørgensen NR, Schwarz P. Osteoporosis in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2008 Mar; 14(2):122-127. Review.
6. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, Fabbri LM, Clini EM. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008 Jun;63(6):487-492.
7. Enright PL, Kronmal RA, Smith VE, Gardin JM, Schenker MB, Manolio TA. Reduced vital capacity in elderly persons with hypertension, coronary heart disease, or left ventricular hypertrophy. The Cardiovascular Health Study. Chest 1995; 107(1): 28-35.
8. Engstrom G, Hedblad B, Valind S, Janzon L. Increased incidence of myocardial infarction and stroke in hypertensive men with reduced lung function. J Hypertens 2001 Feb; 19(2):295-301.
9. Wu Y, Vollmer WM, Buist AS, Tsai R, Cen R, Wu X, Chen P, Li Y, Guo C, Mai J, Davis CE. Relationship between lung function and blood pressure in Chinese men and women of Beijing and Guangzhou. Int J Epidemiol 1998 Feb; 27(1):49-56.
10. Wannamethee SG, Shaper AG, Ebrahim S. Respiratory function and risk of stroke. Stroke 1995 Nov; 26(11):2004-2010.
11. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006 Dec; 28(6):1245-1257. Review.
12. Foschino Barbaro MP, Carpagnano GE, Spanevello A, Cagnazzo MG, Barnes PJ. Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol 2007 Oct-Dec; 20(4):753-763
13. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003; 111(12):1805-1812.
14. Jovici ́c S, Ignjatovi ́c S, Dajak M, Majkíc-Singh N. Analytical performance and clinical efficacy for cardiovascular risk estimation of an Olympus immunoturbidimetric high-sensitivity C-reactive protein assay. Clin Chem Lab Med 2006; 44(2):228-231.
15. Olafsdottir IS, Gislason T, Thjodleifsson B, Olafsson I, Gislason D, Jögi R, Janson C. C-reactive protein levels are increased in non-allergic but not allergic asthma: A multicentre epidemiological study. Thorax 2005 Jun; 60(6):451-454.
16. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006 Jan; 61(1):17-22.
17. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006; 19(3):189-199.
18. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007 Sep 1; 370(9589):797-799.
19. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AMB, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 2007; 370;741-750.
20. ECRH. European Community Respiratory Survey II. 2004 (http://ecrhs.org/ quest.com).
21. Lung Health Study Questionnaire. 2004 (http://bccrc.ca/download/ci/lc02 questionnaire.doc). 2nd edition.
22. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999 Jan; 159(1):179-187.
23. WHO. WHO Collaborating Centre for Drug Statistics Methodology, http://www.whocc.no/atcddd. Norwegian Institute of Public Health, Oslo, Norway.
24. Schols AM, Slangen J, Volovics L,Wouters EF.Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 Jun; 157(6 Pt 1):1791-1797.
25. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L; NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: A life-table analysis. Ann Intern Med 2003 Jan 7; 138(1):24-32.
26. Fabbri LM, Luppi F, Begh́e B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008 Jan; 31(1):204-212.
27. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brøndum E, Nieminen MM, Aine T, Bakke P, Janson C. Mortality in COPD patients discharged from hospital: The role of treatment and co-morbidity. Respir Res 2006 Aug 16; 7:109.
28. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB Sr, O'Donnell CJ. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation 2007 Jul 3; 116(1):39-48. (Pubitemid 47016245)
29. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007 Apr; 56(4):901-911.
30. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT. The use of statins and lung function in current and former smokers. Chest 2007 Dec; 132(6):1764-1771.
31. Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007 Feb; 29(2):279-283.
32. van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, Stam H, Mertens FW, van Domburg RT, Poldermans D. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008 Jul 15; 102(2):192-196.